Patents by Inventor Jedd D. Wolchok

Jedd D. Wolchok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210369795
    Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 2, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
  • Publication number: 20210220494
    Abstract: Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated macrophages, microglia, and/or other cells in a tumor microenvironment using such nanoparticle conjugates. Moreover, diagnostic, therapeutic, and theranostic (diagnostic and therapeutic) platforms featuring such nanoparticle conjugates are described for treating targets in both the tumor and surrounding microenvironment, thereby enhancing efficacy of cancer treatment. Use of the nanoparticle conjugates described herein with other conventional therapies, including chemotherapy, radiotherapy, immunotherapy, and the like, is also envisaged.
    Type: Application
    Filed: April 28, 2017
    Publication date: July 22, 2021
    Inventors: Michelle S. Bradbury, Michael Overholtzer, Cameron Brennan, Barney Yoo, Jedd D. Wolchok, Ulrich Wiesner
  • Patent number: 11045506
    Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 29, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
  • Publication number: 20210177964
    Abstract: The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) vims (Heat-iMVA) or Heat-inactivated vaccinia vims as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies for use as a cancer immunotherapeutic.
    Type: Application
    Filed: November 6, 2018
    Publication date: June 17, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang DENG, Jedd D. WOLCHOK, Taha MERGHOUB, Stewart SHUMAN, Ning YANG
  • Publication number: 20200237902
    Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
    Type: Application
    Filed: January 31, 2020
    Publication date: July 30, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
  • Publication number: 20200232040
    Abstract: Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency X? in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 23, 2020
    Inventors: Marta Luksza, Vinod P. Balachandran, Arnold J. Levin, Jedd D. Wolchok, Taha Merghoub, Steven D. Leach, Timothy A. Chan, Benjamin D. Greenbaum, Michael Laessig
  • Patent number: 10639366
    Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: May 5, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
  • Publication number: 20200113984
    Abstract: The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of tumor regression and/or inhibition of metastasis of a melanoma subject, or a decreased risk of the occurrence or recurrence of melanoma and/or decreased severity of melanoma in a subject not suffering from melanoma at the time of administration. The pharmaceutical composition described herein can be used in conjunction with other therapeutic agents, it can be administered on more than one occasion and it can be combined with administrations of other compositions such as protein or other immunogenic compositions, and/or adjuvants, with beneficial effects to the human or animal subject to which it has been administered.
    Type: Application
    Filed: September 23, 2019
    Publication date: April 16, 2020
    Inventors: Jedd D. WOLCHOK, Francesca AVOGADRI-CONNORS, Robert A. OLMSTED, Maureen MAUGHAN, Taha MERGHOUB
  • Publication number: 20200079860
    Abstract: The present invention provides various compositions and methods useful for the treatment of cancer, such as cancers that are resistant to immune checkpoint blockade and/or are resistant to treatment with PD-1, PD-L1 or CTLA-4 inhibitors. In some embodiments the present invention provides compositions comprising one or more CD40 agonists (e.g. CD40 agonist antibodies), TLR agonists, and/or IL10 receptor inhibitors or IL10 inhibitors, and/or various combinations thereof, optionally together with one or more immune checkpoint inhibitors, and the use of such compositions in treatment of tumors.
    Type: Application
    Filed: August 8, 2016
    Publication date: March 12, 2020
    Inventors: Danny Nejad Khalil, Jedd D. Wolchok, Taha Merghoub
  • Publication number: 20200061184
    Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme Corp.
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Svetlana Sadekova, Rachel Allison Altura, Uyen Phan, Brian B. Haines, Jedd D. Wolchok
  • Publication number: 20200055947
    Abstract: The present invention provides various compositions and methods useful for the treatment of cancer, including, but not limited to, cancers that are resistant to immune checkpoint blockade and/or are resistant to treatment with PD-1, PD-L1 or CTLA-4 inhibitors. In some embodiments the present invention provides compositions comprising “bi-specific activators”—which are nanoparticles having both a CD40 agonist antibody and an antibody specific for a tumor-associated antigen on their surface. In some embodiments such nanoparticles comprise one or more vaccine adjuvants, for example inside the nanoparticles. The present invention also relates to the use of such compositions in the treatment of tumors.
    Type: Application
    Filed: November 4, 2017
    Publication date: February 20, 2020
    Inventors: Danny Nejad Khalil, Jedd D. Wolchok, Taha Merghoub
  • Publication number: 20190375855
    Abstract: The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., melanoma). It relates to chimeric antigen receptors (CARs) that specifically target MDA (e.g., Trp1), and immunoresponsive cells comprising such CARs. The presently disclosed MDA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 12, 2019
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Taha Merghoub, Jedd D. Wolchok, Daniel H. Cymerman, Cailian Liu
  • Patent number: 10251922
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 9, 2019
    Assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, Jedd D. Wolchok
  • Publication number: 20180360892
    Abstract: The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 20, 2018
    Inventors: Eric Pamer, Jedd D. Wolchok, Krista Dubin
  • Publication number: 20180280455
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Application
    Filed: October 20, 2017
    Publication date: October 4, 2018
    Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
  • Publication number: 20180256655
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Application
    Filed: October 20, 2017
    Publication date: September 13, 2018
    Applicants: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
  • Publication number: 20180236062
    Abstract: The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.
    Type: Application
    Filed: February 25, 2016
    Publication date: August 23, 2018
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd D. Wolchok, Taha Merghoub, Peihong Dai, Weiyi Wang
  • Publication number: 20180078592
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Application
    Filed: May 5, 2017
    Publication date: March 22, 2018
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, Memorial Sloan Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
  • Publication number: 20160015760
    Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.
    Type: Application
    Filed: March 4, 2014
    Publication date: January 21, 2016
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, Memorial Sloan Kettering Cancer Center
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Dmitriy Zamarin, James Allison, Jedd D. Wolchok
  • Publication number: 20150037346
    Abstract: Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ILMP) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (CD14+, HLA-DRlow) prior to treatment. Low levels of monocytes of this type (PBM14+HLA-DRlow) indicate a greater likelihood of therapeutic efficacy. In specific exemplary embodiments of the invention, the therapeutic is an antibody to CTLA4, such as ipilimumab or tremelimumab.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: Alexander M. Lesokhin, Jedd D. Wolchok